NASDAQ:CCXI
Delisted
ChemoCentryx Stock News
$51.99
+0 (+0%)
At Close: Jan 27, 2023
ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?
08:49am, Friday, 08'th Oct 2021
ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng
ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug
08:24am, Friday, 08'th Oct 2021
Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated
Why Did ChemoCentryx Shares Soar 70% On Friday Premarket?
08:02am, Friday, 08'th Oct 2021
The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis o
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
07:00am, Friday, 08'th Oct 2021
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time --
Chemocentryx Stock Needs To Hold At Support Or It May Slide Lower
01:10pm, Thursday, 30'th Sep 2021
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower Thursday, although there looks to be no company-evident news to explain the jump in share price. The stock was trending throughout the day on
Why Are ChemoCentryx's Shares Trading Higher Today?
03:54pm, Monday, 27'th Sep 2021
ChemoCentryx Inc's (NASDAQ: CCXI) partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) to market Tavneos (avacopan). Avacopan
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
08:30am, Monday, 27'th Sep 2021
Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with pol
2 Growth Stocks That Could Take Off Before the End of the Year
09:11am, Thursday, 16'th Sep 2021
They've been struggling thus far in 2021, but things could turn around quickly for these companies.
Is the Options Market Predicting a Spike in ChemoCentryx (CCXI) Stock?
11:28am, Wednesday, 15'th Sep 2021
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
ChemoCentryx (CCXI) Up 10.5% Since Last Earnings Report: Can It Continue?
01:16pm, Wednesday, 08'th Sep 2021
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
ChemoCentryx to Participate in Two Upcoming Investor Conferences
08:30am, Thursday, 02'nd Sep 2021
SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two
ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
02:24pm, Tuesday, 24'th Aug 2021
Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021.
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
11:00am, Wednesday, 11'th Aug 2021
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
12:24pm, Tuesday, 10'th Aug 2021
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
11:03pm, Monday, 09'th Aug 2021
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
